N/A
Completed N=184
Oscillatory Contributions to Working Memory and Attention
Young Adults
Source: ClinicalTrials.gov NCT03787134 ↗
Enrolled (actual)
184
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcomePrimary: Behavioral Accuracy: Sub-study 1 — 86.3; 87.1 percentage of correct responses
Summary
The objectives are articulated in the proposal's specific aims:
Aim 1: To test the hypothesis that the cognitive control of unattended memory items (UMI) is implemented by the same frontoparietal mechanisms that control spatial and nonspatial attention.
Aim 2: To test the hypothesis that the selection of visual stimuli, whether from the environment or from WM, is accomplished, in part, by the hijacking of low-frequency oscillatory dynamics that are fundamental to the waking-state physiology of the corticothalamic circuitry of the visual system.
Aim 3: To test the hypothesis that the function of context binding contributes to delay-period activity of the posterior parietal cortex (PPC).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Behavioral Accuracy: Sub-study 1 |
86.3; 87.1 | — |
| PRIMARY Behavioral Accuracy: Sub-study 2 |
85.7; 78.5 | — |
| PRIMARY Behavioral Accuracy: Sub-study 3 |
72; 67 | — |
| PRIMARY Behavioral Accuracy: Sub-study 5 |
86.5; 86 | — |
| PRIMARY Behavioral Accuracy: Sub-study 7 |
11.96; 13.12 | — |
| PRIMARY Reaction Time: Sub-study 1 |
811; 823 | — |
| PRIMARY Reaction Time: Sub-study 2 |
850; 660 | — |
| PRIMARY Reaction Time: Sub-study 3 |
1004; 1070 | — |
| PRIMARY Reaction Time: Sub-study 5 |
970; 990 | — |
| PRIMARY Reaction Time: Sub-study 6 |
750; 675 | — |
| PRIMARY Multivariate Pattern Classification of EEG Data: Sub-study 1 |
.55; .54; .52; .49 | — |
| PRIMARY Multivariate Inverted Encoding Modeling (IEM) Reconstruction: Sub-study 2 |
-0.0108; 0.0033 | .335 |
| PRIMARY Transcranial Magnetic Stimulation (TMS) Effects on EEG Data Component Strengths: Sub-study 1 |
4.57; 4.5; 40.12; 40.45; 46.33; 45.5 | — |
| PRIMARY Alpha Band Power as a Function of Location Relevance in Working Memory: Sub-study 3 |
6.16; 6.19; 6.2; 5.83; 6.05; 6.02 | — |
| PRIMARY The Amplitude of Contralateral Delay Activity (CDA): Sub-study 4 |
.25; .2 | — |
| PRIMARY The Amplitude of the "Contralateral Delay Activity" (CDA): Sub-study 6 |
.6; .75 | — |
| PRIMARY Experiment 2.a. The Amplitude of Multivariate Inverted Encoding Model-reconstructions of Stimulus Location, Derived From the Transcranial Magnetic Stimulation-evoked Response |
— | — |
| PRIMARY Experiment 2.a. Spatially Distributed Phase Coupling Extraction-identified Components of the Transcranial Magnetic Stimulation-evoked Electroencephalography Signal |
— | — |
| PRIMARY Experiment 2.a. Correlation of the Amplitude of Multivariate Inverted Encoding Model-reconstructions of the Location of the Unattended Memory Item With Alpha Band Power. |
— | — |
| PRIMARY Experiment 2.a. Correlation of the Amplitude of Multivariate Inverted Encoding Model-reconstructions of the Location of the Unattended Memory Item With Beta-band Power |
— | — |
| PRIMARY Experiment 3.a. Frequency in the Alpha Band of the EEG as a Function of Retinotopic Location |
— | — |
| PRIMARY Experiment 3.a. Spatially Distributed Phase Coupling Extraction-identified Components of the Electroencephalography Signal From Signals Corresponding to the Attended Location |
— | — |
| PRIMARY Experiment 4.a. Reaction Time Assess as Latency to Press Response Button After Onset of Critical Stimulus. |
— | — |
| PRIMARY Experiment 4.a. Power in the Alpha Band of the EEG as a Function of Retinotopic Location |
— | — |
| PRIMARY Experiment 4.a. Frequency in the Alpha Band of the EEG as a Function of Retinotopic Location |
— | — |
| PRIMARY Experiment 4.a. Spatially Distributed Phase Coupling Extraction-identified Alpha-band Components of the Electroencephalography Signal From Signals Corresponding to the Attended Location |
— | — |
| PRIMARY Experiment 6. Multivariate Inverted Encoding Modeling of the EEG Signal to Determine Whether or Not Contextual Information is Carried in This Signal |
— | — |
Eligibility Criteria
Inclusion Criteria
- Age of # 18 <36. - Right-handed.
- Be in good health determined by the investigator on basis of medical history, physical and neurological exam; for "EEG-only" sessions no physical or neurological exams will be performed;
- Female subjects must be two years past menopause, surgically sterile or practicing a medically acceptable method of birth control (does not apply to "EEG-only" sessions);
- Female subjects must not be pregnant.
- Able to understand and speak English.
- Able to provide written consent prior to admission
Exclusion Criteria
- History of epilepsy, stroke, brain surgery, cranial metal implants, structural brain lesion, devices that may be affected by TMS or tCS(pacemaker, medication pump, cochlear implant, implanted brain stimulator); - Women who are breast-feeding (self report)*;
- History of head trauma with loss of consciousness for greater than 5 minutes;
- Any history of seizures;
- Any family history of seizures*;
- Diabetes requiring insulin treatment*;
- A serious heart disorder or subjects who have had a heart attack within the last 3 months;
- Subjects who meet DSM-IV criteria for alcohol /drug abuse problems within the last six months;
- Any current Axis I or II diagnoses or past Axis I diagnoses;
- Required use of medication that affects CNS function;
- A subject with metallic implants, such as prostheses, shrapnel or aneurysm clip-S, or persons with electronic implants, such as cardiac pacemakers. The magnetic field generated by the MR machine can cause a displacement or malfunctioning of these devices*;
- The female subject who is pregnant or planning to become pregnant; or a female subject of child-bearing potential who is not practicing a medically acceptable form of birth control*;
- The subject has had a diagnosis of cancer in the past 3 years and/or has active neoplastic disease;
- The investigator anticipates that the subject will be unable to comply with the protocol.
- Prohibited Concomitant Treatment: Any investigational medication; antipsychotic, antidepressant; or ECT; Other psychotropic medications including sedative hypnotics (excluding chloral hydrate zaleplon); sumatriptan (and similar agents); anxiolytics and herbals (e.g., St. John's Wort, Kava Kava); an introduction or change in intensity of psychotherapy; any nonpsychopharmacologic drug with psychotropic effects (e.g., antihistamines, beta blockers).
- Colorblindness
- Poor or Uncorrected Vision
- History of fainting/syncope
Data sourced from ClinicalTrials.gov (NCT03787134). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.